Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nedaplatin + paclitaxel versus carboplatin + paclitaxel for epithelial ovarian cancer
ChiCTR-TRC-11001333Phase 4Completed
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nedaplatin, paclitaxel and carboplatin in epithelial ovarian cancer (EOC) (2 arms), sponsored by Shanghai General Hospital. Primary endpoints: Overall survival, CA125 and 2 more. Started Aug 2010; status: completed.
02
Drugs
nedaplatinpaclitaxelcarboplatin
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on ChiCTR-TRC-11001333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001333.